Ablation

Worldwide Tumor Ablation Industry to 2026 - Key Players Include Medtronic, Boston Scientific and Endocare Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, July 2, 2021
Health, Oncology, Medicine, Interventional radiology, Medical specialties, Clinical medicine, Ablation, Cancer, Oncology, Surgical oncology, Interventional oncology, Microwave ablation

The "Tumor Ablation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tumor Ablation Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering.
  • The global tumor ablation market reached a value of US$ 634.2 Million in 2020.
  • Looking forward, the publisher expects the global tumor ablation market to grow at a CAGR of 12% during 2021-2026.
  • Tumor ablation refers to a minimally invasive (MI) technique that is conducted to treat tumors of the kidney, liver, bones and lungs.

CardioFocus Appoints Stephan Ogilvie as Chief Financial Officer

Retrieved on: 
Tuesday, June 29, 2021
Cardiac arrhythmia, NuVasive, Atrial fibrillation, Ogilvie, Ablation

MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ -- CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the appointment of Stephan Ogilvie as its Chief Financial Officer.

Key Points: 
  • MARLBOROUGH, Mass., June 29, 2021 /PRNewswire/ -- CardioFocus, Inc. , a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), today announced the appointment of Stephan Ogilvie as its Chief Financial Officer.
  • Previously Mr. Ogilvie served as Vice President, Corporate Development at NuVasive, where he led a variety of key functions, including mergers and acquisitions and the expansion of the company's global sales infrastructure.
  • "Steve possesses deep experience in the healthcare industry, including a diverse background across key operational roles at medical device companies, as well as within the medical device sector on Wall Street," said Burke T. Barrett, chief executive officer and president of CardioFocus.
  • "CardioFocus is bringing important innovation to the Afib ablation space with its recently launched HeartLight X3," said Mr. Ogilvie.

Radiofrequency Ablation Devices Market Research Report 2021 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Medical devices, Health, Medicine, Interventional radiology, Medical terminology, Radiofrequency ablation, Surgical oncology, Health care, Ablation

The "Radiofrequency Ablation Devices Market Research Report: By Component (Catheter Systems, Generators, Accessories), Application (Oncology, Cardiology, Pain Management), End User (Hospitals, Ambulatory Surgical Centers) - Global Industry Analysis and Demand" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Radiofrequency Ablation Devices Market Research Report: By Component (Catheter Systems, Generators, Accessories), Application (Oncology, Cardiology, Pain Management), End User (Hospitals, Ambulatory Surgical Centers) - Global Industry Analysis and Demand" report has been added to ResearchAndMarkets.com's offering.
  • The radiofrequency (RF) ablation devices market stood at $3,173.5 million in 2019, and it is projected to reach $11,080.3 million by 2030, exhibiting a 12.6% CAGR during the forecast period (2020-2030).
  • The categories under the component segment of the radiofrequency ablation devices market are catheter systems, accessories, and generators.
  • During the forecast period, the Asia-Pacific (APAC) region is expected to register the fastest growth in the global radiofrequency ablation devices market.

IceCure Medical Announces Exclusive $6.6M Distribution Agreement to Sell ProSense™ Cryoablation System in Brazil

Retrieved on: 
Monday, June 7, 2021
Interventional radiology, Cryoablation, Ablation, Tel Aviv Stock Exchange

CAESAREA, Israel, June 7, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that it has entered into an exclusive distribution agreement with KTRFIOS IMPORTACAO E EXPORTACAO LTDA (the "Distributor") to sell the Company's ProSense Cryoablation System in Brazil, with the largest population in Latin America.

Key Points: 
  • CAESAREA, Israel, June 7, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that it has entered into an exclusive distribution agreement with KTRFIOS IMPORTACAO E EXPORTACAO LTDA (the "Distributor") to sell the Company's ProSense Cryoablation System in Brazil, with the largest population in Latin America.
  • This agreement follows similar agreements signed by IceCure in the United Arab Emirates, India, Thailand, and other countries, provides further validation for the ProSense cryoablation technology and continues the Company's mission to bring this technology to all geographies and thus increase sales.
  • The system is marketed and sold worldwide, after receiving FDA and CE approvals.
  • In view of the foregoing, this information might not materialize or materialize significantly differently than described above.

Gynesonics Announces Positive Coverage Policy Decision Published by Cigna for Treatment of Uterine Fibroids with the Sonata System

Retrieved on: 
Thursday, June 3, 2021
Professional services, Health, Medical devices, Surgery, Insurance, Managed care, General Health, Medicine, Clinical medicine, Medical specialties, Gynaecological neoplasia, Uterine fibroid, Surgical oncology, Interventional radiology, Gynecological surgery, Transcervical, Radiofrequency ablation, Uterus, Ablation, Sonata System, Gynesonics, SONATA SYSTEM, GYNESONICS

The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.

Key Points: 
  • The Sonata technology platform integrates the first and only commercial intrauterine ultrasound system with a proprietary advanced radiofrequency ablation device, providing an incision-free, uterus-preserving, transcervical treatment for symptomatic uterine fibroids.
  • Fibroids are treated from within the uterus, so treatment with the Sonata System requires no incisions, no tissue is surgically removed, and the uterus is retained.
  • This policy opens the way for their members to have the Sonata Procedure, the least invasive radio frequency ablation treatment for uterine fibroids, said Chris Owens, President and CEO of Gynesonics.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

New Guidance from the American College of Obstetricians and Gynecologists for Fibroid Management Supports Incisionless Transcervical Radiofrequency Ablation as a Uterus-Preserving Treatment Option

Retrieved on: 
Tuesday, June 1, 2021
Surgery, Women, FDA, Clinical trials, Biotechnology, Other Health, Health, Consumer, Pharmaceutical, Medicine, Clinical medicine, Neoplasms, Interventional radiology, Gynaecological neoplasia, Uterine fibroid, Radiofrequency ablation, Transcervical, Ablation, Sonata System, Gynesonics, SONATA SYSTEM, GYNESONICS

We are pleased that ACOG included transcervical radiofrequency ablation of fibroids in their Practice Bulletin.

Key Points: 
  • We are pleased that ACOG included transcervical radiofrequency ablation of fibroids in their Practice Bulletin.
  • This comes on the heels of the two-part expert consensus recommendation of a new fibroid treatment algorithm in Europe incorporating transcervical radiofrequency ablation.
  • Im particularly pleased to see ACOG recognize the efficacy of transcervical radiofrequency ablation of fibroids.
  • Gynesonics has developed the Sonata System for diagnostic intrauterine imaging and transcervical treatment of symptomatic uterine fibroids.

Acutus Medical Receives FDA Approval to Initiate US Atrial Fibrillation IDE Trial with the AcQBlate® FORCE Sensing Ablation System

Retrieved on: 
Thursday, May 27, 2021
Catheter ablation, Circulatory system, Cardiac arrhythmia, Clinical medicine, Cardiovascular system, Atrial fibrillation, Arrhythmia, Heart, Ablation, Sensei robotic catheter system, Topera Medical

CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (AF) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System.

Key Points: 
  • CARLSBAD, Calif., May 27, 2021 (GLOBE NEWSWIRE) -- Acutus Medical (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced FDA approval for the company to initiate its Atrial Fibrillation (AF) Investigational Device Exemption (IDE) clinical trial for the AcQBlate Force Sensing Ablation Catheter and System.
  • In contrast to most contemporary ablation systems, the AcQBlate Force Catheter and System can operate both in a stand-alone manner or in conjunction with compatible 3D mapping systems.
  • The new ablation system is comprised of Acutus AcQBlate Force Catheter and Qubic Force module and seamlessly integrates with the Qubic RF generator and Qiona irrigation pump.
  • Ariyarathna N. et al., Role of Contact Force Sensing in Catheter Ablation of Cardiac Arrhythmias: Evolution or History Repeating Itself?

New Fibroid Management Guidance from the American College of Obstetricians and Gynecologists Supports Laparoscopic Radiofrequency Ablation (Lap-RFA) as a Minimally Invasive, Uterine Preserving Treatment Option

Retrieved on: 
Monday, May 24, 2021
Health, Medical devices, Consumer, Women, Surgery, General Health, Radiology, Medicine, Clinical medicine, Medical specialties, Interventional radiology, Surgical oncology, Gynaecological neoplasia, Uterine fibroid, Radiofrequency ablation, Ablation, Uterine artery embolization, Uterine myomectomy

Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, announced today that the American College of Obstetricians and Gynecologists (ACOG), in its updated guidance for Management of Symptomatic Uterine Leiomyomas , supports the use of laparoscopic radiofrequency ablation (Lap-RFA) for the treatment of uterine fibroids.

Key Points: 
  • Hologic, Inc. (Nasdaq: HOLX), a global leader in womens health, announced today that the American College of Obstetricians and Gynecologists (ACOG), in its updated guidance for Management of Symptomatic Uterine Leiomyomas , supports the use of laparoscopic radiofrequency ablation (Lap-RFA) for the treatment of uterine fibroids.
  • ACOGs updated guidance in Practice Bulletin Number 228 will help physicians and patients considering fibroid treatment recognize Lap-RFA as a safe and effective uterine sparing option.
  • The Acessa procedure provides a minimally invasive, uterine-sparing surgical option for women with symptomatic fibroids who would otherwise require more invasive intervention.
  • This treatment combines laparoscopic ultrasound with radiofrequency ablation to destroy fibroid tissue through coagulation necrosis.

Positive Interim Results from IceCure Medical's ICE3 Clinical Trial for Breast Cancer Treatment by Freezing with the ProSense® Cryoablation System Presented at the 2021 ASBrS Meeting

Retrieved on: 
Tuesday, May 4, 2021
Clinical medicine, Medicine, Medical specialties, Interventional radiology, Cryoablation, Breast cancer, Ablation, Interventional oncology

b'CAESAREA, Israel, May 4, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the minimally invasive cryoablation ProSense System that destroys tumors by freezing, today announced interim results from the Company\'s ICE3 clinical trial for cryoablation of small low-risk breast cancer tumors.

Key Points: 
  • b'CAESAREA, Israel, May 4, 2021 /PRNewswire/ -- IceCure Medical Ltd. (TASE: ICCM) ("IceCure" or the "Company"), developer of the minimally invasive cryoablation ProSense System that destroys tumors by freezing, today announced interim results from the Company\'s ICE3 clinical trial for cryoablation of small low-risk breast cancer tumors.
  • Recovery time is minimal and cosmetic outcomes are excellent with little loss of breast tissue and no scarring.
  • Now, this trial is underscoring the efficacy and safety of the procedure for this patient group.
  • Patients were treated with IceCure\'s ProSense Cryoablation System, a minimally-invasive approach to directly target and freeze tumors.

IPG Photonics Reports First Quarter 2021 Financial Results

Retrieved on: 
Tuesday, May 4, 2021
Energy, IPG Photonics, Physical sciences, Natural sciences, Valentin Gapontsev, Solar cell, Gapontsev, Welding, Photonics, Ablation, IPG, Electric vehicle battery

These drove both year-over-year and sequential increases in sales, despite typical seasonality, helping us achieve our best first quarter results since 2018, which was a record year, and a solid start to 2021," said Dr. Valentin Gapontsev, IPG Photonics\' Executive Chairman of the Board.

Key Points: 
  • These drove both year-over-year and sequential increases in sales, despite typical seasonality, helping us achieve our best first quarter results since 2018, which was a record year, and a solid start to 2021," said Dr. Valentin Gapontsev, IPG Photonics\' Executive Chairman of the Board.
  • "We saw firm demand in welding applications, growth in electric vehicle battery production and solar cell manufacturing that helped our results.
  • Materials processing sales increased 45% year over year due to higher sales in welding, cutting, solar cell manufacturing, sintering and ablation applications.
  • During the first quarter, IPG generated $88 million in cash from operations.